Sima Sistani helped push the company into the GLP-1 drug space with the $106 million acquisition of Sequence.

Drug companies are under fire for the high cost of Ozempic and simlar meds. A doctor said patients who can't afford it may ...

Sima Sistani, CEO of WeightWatchers, announced her departure from the weight-loss company, which has struggled to adapt in ...

The global weight management market is poised for significant growth over the next decade, driven by increasing awareness of ...

Did she gain the weight back? Here's what she says, plus more mindful takeaways for the reported 15 million Americans who ...